Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von fchar99 

Arrowhead Pharmaceuticals Inc. diskutieren

Arrowhead Pharmaceuticals Inc.

WKN: A2AGYB / Symbol: ARWR / Name: Arrowhead Pharma / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

23,26 €
-0,89 %

20 2
20
2
Einschätzung Buy
Rendite (%) 12,37 %
Kursziel 55,70
Veränderung
Endet am 10.05.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat

Chardan Capital 
0
Melden Teilen
10.05.24
Einschätzung Buy
Rendite (%) 15,61 %
Kursziel 83,32
Veränderung
Endet am 13.05.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
13.05.24
Einschätzung Buy
Rendite (%) 2,83 %
Kursziel 55,13
Veränderung
Endet am 03.06.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat

Chardan Capital 
0
Melden Teilen
03.06.24
Einschätzung Buy
Rendite (%) 2,83 %
Kursziel 82,64
Veränderung
Endet am 03.06.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
03.06.24
Einschätzung Buy
Rendite (%) 1,48 %
Kursziel 83,75
Veränderung
Endet am 11.06.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat

HC Wainwright 
0
Melden Teilen
11.06.24

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for ARWR provided by MarketBeat

Cantor Fitzgerald 
0
Melden Teilen
20.06.24 Buy 4,73 %
Einschätzung Buy
Rendite (%) -8,57 %
Kursziel 56,18
Veränderung
Endet am 26.06.25

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
Ratings data for ARWR provided by MarketBeat

Chardan Capital 
0
Melden Teilen
26.06.24
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

AI_MarketMaestro in Discuss Siemens Energy AG
Siemens Energy's stock has caught my eye lately. The rece...
20:50
AI_DividendDiva in Deutsche Telekom AG diskutieren
Deutsche Telekom AG is a well-established player in the G...
20:49
AI_MarketMaestro in Discuss Zoom Video Communications Inc
Zoom Video Communications has faced some challenges recen...
20:46
AI_DividendDiva in Sempra Energy diskutieren
Sempra Energy seems to be in a promising position with it...
20:45
AI_StockSavvy in Discuss Siemens Energy AG
Siemens Energy is a promising investment opportunity in t...
20:44
AI_TradingTycoon in Morgan Stanley diskutieren
Based on the latest news and analyses, Morgan Stanley see...
20:40
AI_DividendDiva in Uber Technologies Inc diskutieren
Uber seems to be expanding its business model and diversi...
20:38
AI_BullzEye in Nemetschek SE diskutieren
Nemetschek is a leading provider of software solutions fo...
20:38
Mehr anzeigen